Welcome to our dedicated page for JIN MED INTL LTD. SEC filings (Ticker: ZJYL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jin Medical International Ltd. (ZJYL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Jin Medical files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which together present information on its operations in wheelchair manufacturing, rehabilitation medical equipment, living aids products and related health and beauty devices.
Through these filings, investors can review unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and details about the company’s manufacturing facilities in Changzhou, Taizhou and Chuzhou in China. Certain 6-K reports also describe material events, such as the launch of production at the Chuzhou intelligent manufacturing facility, appointment of independent directors and updates related to capital markets activities and registration statements on Form F-3.
Listing-related disclosures, including Nasdaq notifications about minimum bid price requirements and shareholder distribution rules, are typically reported via 6-K filings or referenced in company press releases. These documents help readers understand Jin Medical’s compliance status, potential remedial actions and associated timelines. Corporate governance information, such as committee assignments and director backgrounds, can also appear in these reports.
On Stock Titan, AI-powered tools summarize lengthy filings so users can quickly identify key points in Jin Medical’s 20-F and 6-K submissions, including segment information, risk discussions and updates on rehabilitation and assistive technology initiatives. Real-time integration with the SEC’s EDGAR system allows timely access to new filings, while structured views of exhibits and XBRL data support deeper analysis of financial and operational trends relevant to Jin Medical’s role in the surgical and medical instrument manufacturing sector.
Jin Medical International Ltd., a Cayman Islands holding company, files its annual 20-F describing a business that designs and manufactures wheelchairs and living aids mainly for Japan and China through a China-based VIE structure. Public shareholders own the Cayman entity, not the PRC operating company.
The filing highlights structural and regulatory risks around the VIE contracts, potential PRC policy changes, cybersecurity and overseas listing rules, and the U.S. Holding Foreign Companies Accountable Act, while noting its auditors are currently subject to PCAOB inspections. Customer concentration is high: sales to Nissin and its subsidiaries were approximately 57.3%, 78.2% and 80.5% of revenue for fiscal 2025, 2024 and 2023.
The company also discloses restrictions on capital flows, foreign exchange and dividend payments from mainland China, and reliance on PRC subsidiaries and the VIE for cash generation. As of September 30, 2024, it reports cash of about $8.1 million, short-term investments of $18.6 million, total current assets of roughly $42.8 million and total current liabilities of about $17.2 million.
Jin Medical International Ltd. furnished a CEO fireside chat outlining its strategic priorities, capital plans, and manufacturing expansion. The CEO described a potential reverse stock split as both a Nasdaq compliance step and a broader “strategic reset” to realign the capital structure with long-term fundamentals and market perception.
Management highlighted three priorities: clearer, more frequent communication on strategic and operational milestones, disciplined capital allocation into manufacturing capacity, product certification and market expansion, and a long-term view that reflects medical-device regulatory cycles. Operating leverage is expected mainly from manufacturing efficiency, supply chain integration and product mix optimization.
The new Chuzhou factory, a 430,000 square foot facility in Anhui Province, is described as a cornerstone asset, targeting full-capacity production by the end of April 2026 to improve automation, quality control, cost per unit and global competitiveness. Jin Medical already runs two plants totaling about 230,000 square feet and sells over 30 wheelchair models through more than 40 distributors in China and over 20 internationally. The CEO also addressed industry growth drivers from aging populations and rehabilitation needs, and explained the company’s approach to US–China geopolitical risk via supply chain diversification, regional manufacturing flexibility and regulatory compliance. The company reiterated standard forward-looking statement cautions.
Jin Medical International Ltd. reported the results of its 2026 Extraordinary General Meeting of Shareholders. Shareholders holding 128,595,806.60 ordinary shares were present in person or by proxy, exceeding the quorum threshold out of 156,547,100 ordinary shares entitled to vote as of December 30, 2025.
Shareholders approved several special and ordinary resolutions, including adopting a second amended and restated memorandum and articles of association to create a dual class share capital structure. They also approved the 2026 Equity Incentive Plan, authorizing the board to issue up to 13,000,000 Class A ordinary shares as equity awards to directors, officers, employees, and other service providers.
Additional resolutions included authority related to matters contingent on the change of authorized share capital and authorization to adjourn the meeting if necessary. All resolutions received strong support, with votes for each proposal significantly exceeding votes against and abstentions.
Jin Medical International Ltd. filed a Form 6-K to share a press release about an upcoming management fireside chat and an updated corporate website. The fireside chat, led by the CEO and management team, will be webcast at 8:00 pm EST on February 1, 2026 via the company’s site.
The discussion is expected to cover the company’s recent strategic priorities and long-term growth considerations. Jin Medical, a China-based provider of rehabilitation medical equipment, highlights its wheelchair and living aids business, multiple manufacturing plants, expanding production footprint, and distribution network in China, Japan, and other international markets.
Jin Medical International Ltd. reports operational progress at its new manufacturing facility in Chuzhou, Anhui Province, China. Its wholly owned subsidiary Zhongjin Medical Equipment (Anhui) Co., Ltd. has completed key regulatory steps, obtaining a license for Class I medical device production on December 29, 2025.
The Chuzhou facility, with approximately 430,000 square feet, is in the final construction phase and is projected to reach full-capacity production by the end of April 2026. Once fully operational, it is expected to provide annual capacity of 200,000 units of mid-to-high-end electric wheelchairs and senior mobility scooters.
Located in the Yangtze River Delta manufacturing hub, the facility is intended to enhance Jin Medical’s manufacturing scale, supply chain resilience, and ability to serve domestic and international demand. The company emphasizes that these expectations are forward-looking and subject to various business, regulatory, and economic risks.
Jin Medical International Ltd. filed a Form 6-K to share a press release announcing that its management team will host a fireside chat on February 1, 2026. The discussion will focus on the Company’s strategic priorities and considerations related to its capital structure, while also addressing recent market developments and the framework of its ongoing strategic planning efforts.
Management states that Jin Medical maintains what it believes is a strong liquidity position and is actively evaluating a range of strategic options aimed at enhancing its competitive position in the rehabilitation medical equipment industry. The Company presents these initiatives as being undertaken from a position of operational and financial strength, and highlights its established manufacturing footprint and distribution network in China and international markets.
Jin Medical International Ltd. has called a 2026 extraordinary general meeting on January 30, 2026 to ask shareholders to approve a major overhaul of its capital structure and governance documents. The company proposes creating a dual-class share structure with 900,000,000 Class A ordinary shares carrying one vote each and 100,000,000 Class B ordinary shares carrying thirty votes each. As part of this recapitalization, it plans to issue approximately 136,547,100 Class A shares pro rata to existing shareholders (other than Jolly Harmony Enterprises Limited) and approximately 20,000,000 Class B shares to Jolly Harmony, then repurchase and cancel the current 156,547,100 ordinary shares.
Shareholders are also being asked to approve new second amended and restated memorandum and articles of association to reflect the dual-class structure, and to authorize up to three potential share consolidations over the next two years, each triggered at the Board’s discretion when the Class A share price is below US$1.00. In addition, the Board seeks approval of a 2026 Equity Incentive Plan allowing issuance of up to 13,000,000 Class A shares as equity awards, and authority to adjourn the meeting if more time is needed to secure votes. The Board unanimously recommends voting in favor of all five proposals.
Jin Medical International Ltd. submitted a Form 6‑K that attaches unaudited condensed consolidated financial statements covering the periods ended
Jin Medical International Ltd. (Nasdaq: ZJYL) has filed a Form F-3 universal shelf registration that would allow it to issue up to $300 million of ordinary shares, warrants, debt securities, rights or units on a continuous or delayed basis. The filing gives the company maximum flexibility in timing, structure and pricing of future capital raises. Each specific offering will be detailed in a subsequent prospectus supplement.
The company’s current public float is approximately $34.4 million (based on 37.8 million non-affiliate shares at $0.91 on 30 Apr 2025). Because its float is below $75 million, General Instruction I.B.5 limits aggregate primary offerings under the F-3 to one-third of public float in any 12-month period—about $11.5 million at today’s level. Ordinary shares last traded at $0.6594 on 24 Jun 2025.
Jin Med is a Cayman holding company; operations are conducted in China through a variable-interest-entity (VIE), Changzhou Zhongjin Medical Equipment Co. Ltd. Investors buy equity in the Cayman entity and have only contractual, not ownership, exposure to the PRC operating company. The prospectus emphasizes extensive regulatory and enforcement risks associated with this structure, including potential PRC disallowance that could render the securities worthless.
The filing states the company is an emerging growth company; it is not currently subject to CAC cybersecurity review and, as an existing overseas issuer, is not immediately required to file with the CSRC for the shelf registration. Future offerings, however, must be filed with the CSRC within three business days of completion.
Key investor takeaways:
- Shelf capacity: up to $300 million, but annual usage capped by I.B.5.
- Potential dilution risk given current float and low share price.
- Material VIE, PRC policy and regulatory uncertainties.
- No immediate CAC or CSRC obstacles identified as of 15 May 2025.